This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Should Vanguard Russell 1000 Value ETF (VONV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VONV
These 3 Blue-Chip Stocks Are Great Shields for Volatility
by Derek Lewis
Investing in blue-chip stocks is a great way to add a higher level of defense to a portfolio. After all, defense wins ballgames.
5 Large-Cap Stocks Likely to Gain on Q2 Earnings Next Week
by Nalak Das
Five large-cap companies will report second-quarter 2022 earnings results next week. These are: SYF, JNJ, JBHT, TFC and CFG.
Is Vanguard High Dividend Yield ETF (VYM) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VYM
Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)?
by Zacks Equity Research
Sector ETF report for PJP
Why Johnson & Johnson (JNJ) Could Beat Earnings Estimates Again
by Zacks Equity Research
Johnson & Johnson (JNJ) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Johnson & Johnson (JNJ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is iShares Core Dividend Growth ETF (DGRO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRO
Is WisdomTree U.S. Quality Dividend Growth ETF (DGRW) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for DGRW
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $178.35, moving +0.04% from the previous trading session.
What Lies Ahead for Dow ETF in Q2 Earnings?
by Sweta Killa
With some of the blue-chip companies expected to report an earnings surprise, investors should closely monitor the movement of the Dow ETF and grab an opportunity that arises from a surge in any of the 30 stocks.
Should iShares S&P 500 Value ETF (IVE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IVE
Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PWV
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
Should Vanguard S&P 500 Value ETF (VOOV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VOOV
This is Why Johnson & Johnson (JNJ) is a Great Dividend Stock
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes? Let's find out.
Should Vanguard Mega Cap Value ETF (MGV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for MGV
Is iShares Core S&P U.S. Value ETF (IUSV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IUSV
Should Invesco S&P 500 Low Volatility ETF (SPLV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) closed the most recent trading day at $178.14, moving -0.77% from the previous trading session.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
by Zacks Equity Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM